Sight Sciences Inc. (NASDAQ:SGHT) has obtained a court order confirming a jury’s finding that Alcon Inc. willfully infringed three patents related to glaucoma treatment technology. The order was issued on March 27, 2026, by the U.S. District Court for the District of Delaware.
The ruling grants Sight Sciences $34 million in damages. This includes $5.5 million in lost profits and $28.5 million in royalty payments tied to Alcon’s Hydrus Microstent sales from the product’s commercial launch up to the jury verdict. In addition, the court ordered an ongoing royalty equal to 10% of Hydrus revenue through November 10, 2028, when the final patent involved in the case expires.
The lawsuit, first filed on September 16, 2021, centered on three Sight Sciences patents: U.S. Patent Nos. 8,287,482, 9,370,443, and 11,389,328. The jury determined that Alcon’s Hydrus Microstent device infringed each of these patents.
A final judgment will be issued once supplemental damages and pre-judgment interest are calculated using additional financial data from Alcon. The decision can still be appealed by Alcon and could also be influenced by ex parte reexamination proceedings the company initiated with the U.S. Patent and Trademark Office.
“We are pleased with the results of the ruling and the recognition of our strong intellectual property portfolio in interventional glaucoma,” said Paul Badawi, co-founder and chief executive officer of Sight Sciences.
Sight Sciences said it expects to record a $5.4 million success fee as an operating expense, payable to law firm Cooley LLP, which represented the company in the case. The company indicated that this fee will be excluded from its non-GAAP adjusted operating expense calculations.